Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.70 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 10/20 | 0.53 |
| ▸ | MTOR | P42345 | 8/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815148 | 0.82 | PIK3CA (1.00) | PIK3CA | |
| SCHEMBL881133 | 0.80 | PIK3CA (0.54) | PIK3CAMAP3K12AKT1MTOR | |
| SCHEMBL881112 | 0.80 | PIK3CA (0.54) | PIK3CAMAP3K12AKT1MTOR | |
| SCHEMBL12486629 | 0.79 | IGF1R (0.53) | PIK3CAIGF1R | |
| SCHEMBL6319164 | 0.77 | PIK3CA (0.58) | PIK3CAIGF1R | |
| SCHEMBL10327965 | 0.77 | PIK3CA (0.74) | PIK3CAMAP3K12AKT1MTOR | |
| SCHEMBL881093 | 0.76 | PIK3CA (0.55) | PIK3CAAKT1MTORIGF1R | |
| SCHEMBL10327901 | 0.75 | PIK3CA (0.68) | PIK3CA | |
| SCHEMBL3451413 | 0.75 | NPSR1 (0.67) | PIK3CAIGF1R | |
| SCHEMBL2675087 | 0.74 | PIK3CA (0.53) | PIK3CAMAP3K12AKT1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | PIK3CA 5/4885MAP3K12 60/4885AKT1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.